These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20701066)

  • 41. The interactions of dietary tomato powder and soy germ on prostate carcinogenesis in the TRAMP model.
    Zuniga KE; Clinton SK; Erdman JW
    Cancer Prev Res (Phila); 2013 Jun; 6(6):548-57. PubMed ID: 23592738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
    Sargeant AM; Rengel RC; Kulp SK; Klein RD; Clinton SK; Wang YC; Chen CS
    Cancer Res; 2008 May; 68(10):3999-4009. PubMed ID: 18483287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
    Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
    Murakami K; Sakukawa R; Sano M; Hashimoto A; Shibata J; Yamada Y; Saiki I
    Clin Cancer Res; 1999 Sep; 5(9):2304-10. PubMed ID: 10499597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP; Ho RL; Chen GG; Lai PB
    Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
    Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
    Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice.
    Singh SV; Powolny AA; Stan SD; Xiao D; Arlotti JA; Warin R; Hahm ER; Marynowski SW; Bommareddy A; Potter DM; Dhir R
    Cancer Res; 2008 Nov; 68(22):9503-11. PubMed ID: 19010926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
    Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
    Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model.
    Venier NA; Yamamoto T; Sugar LM; Adomat H; Fleshner NE; Klotz LH; Venkateswaran V
    Prostate; 2015 Sep; 75(12):1300-11. PubMed ID: 26047020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endothelial-specific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism.
    Patenaude A; Fuller M; Chang L; Wong F; Paliouras G; Shaw R; Kyle AH; Umlandt P; Baker JH; Diaz E; Tong J; Minchinton AI; Karsan A
    Cancer Res; 2014 May; 74(9):2402-11. PubMed ID: 24599126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
    Wechter WJ; Leipold DD; Murray ED; Quiggle D; McCracken JD; Barrios RS; Greenberg NM
    Cancer Res; 2000 Apr; 60(8):2203-8. PubMed ID: 10786685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
    Kakodkar NC; Peddinti RR; Tian Y; Guerrero LJ; Chlenski A; Yang Q; Salwen HR; Maitland ML; Cohn SL
    Pediatr Blood Cancer; 2012 Oct; 59(4):642-7. PubMed ID: 22147414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences.
    Montico F; Kido LA; San Martin R; Rowley DR; Cagnon VH
    Prostate; 2015 Oct; 75(14):1643-61. PubMed ID: 26184673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
    Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
    Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
    Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
    J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A therapeutically relevant, 3,3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78kDa (GRP78).
    Nayak D; Amin H; Rah B; Ur Rasool R; Sharma D; Gupta AP; Kushwaha M; Mukherjee D; Goswami A
    Chem Biol Interact; 2015 May; 232():58-67. PubMed ID: 25794856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
    Raza A; Franklin MJ; Dudek AZ
    Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.